Stay updated on SEA-CD70 Safety in Myeloid Malignancies Clinical Trial
Sign up to get notified when there's something new on the SEA-CD70 Safety in Myeloid Malignancies Clinical Trial page.

Latest updates to the SEA-CD70 Safety in Myeloid Malignancies Clinical Trial page
- Check4 days agoChange DetectedThe date has been updated from March 7, 2025, to March 11, 2025.SummaryDifference0.3%
- Check11 days agoChange DetectedThe page has updated the reference to Seagen, clarifying its relationship as a subsidiary of Pfizer, and has changed the date from October 9, 2024, to March 7, 2025.SummaryDifference3%
- Check18 days agoNo Change Detected
- Check26 days agoChange DetectedThe page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.SummaryDifference5%
- Check33 days agoNo Change Detected
- Check40 days agoChange DetectedThe page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with a contact email for assistance.SummaryDifference6%
- Check47 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.3%
- Check61 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.3%
Stay in the know with updates to SEA-CD70 Safety in Myeloid Malignancies Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SEA-CD70 Safety in Myeloid Malignancies Clinical Trial page.